Protein loss and medium cut-off haemodialysis
Mohamed Belmouaz(Centre de Référence des Maladies Autoinflammatoires et des Amyloses), Frank Bridoux(Université de Poitiers), Audrey Sibille(Université de Poitiers), Antoine Thierry(Université de Poitiers), L Dufour(Université de Poitiers), Laure Écotière(Centre National de la Recherche Scientifique), Jean‐Claude Lecron(Université de Poitiers)
Cited by 6
Related Papers
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases
|Kidney International|2021|809
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group
|Nature Reviews Nephrology|2018|544
Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant
|Blood|2012|543
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
|New England Journal of Medicine|2007|520